Amphastar Q4 Revenue Falls 1.8% and EPS Drops to $0.73
Amphastar Pharmaceuticals posted Q4 revenue of $183.11 million, down 1.8% year-over-year and missing the $194.03 million estimate, while EPS fell to $0.73 from $0.92 for a 24.5% shortfall. BAQSIMI sales rose 11.8% to $46.71 million but all other products except Lidocaine saw year-over-year declines.
1. Q4 Financial Results
Amphastar reported $183.11 million in revenue for the quarter ended December 2025, 1.8% below year-ago levels and 5.6% under the $194.03 million consensus estimate. Earnings per share declined to $0.73 from $0.92 a year ago, missing the $0.97 forecast by 24.5%.
2. Product-Level Revenue Breakdown
BAQSIMI sales rose 11.8% year-over-year to $46.71 million but trailed the $52.07 million estimate. Primatene MIST revenue dipped 3.5% to $27.93 million versus a $31.48 million projection, Epinephrine fell 8.6% to $17.09 million, Lidocaine grew 3.5% to $14.90 million, and Glucagon plunged 45% to $14.08 million, though it exceeded the $10.59 million target.